In vitro activity of imipenem-relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017.
β-lactam- and multidrug-resistant (MDR) Gram-negative bacilli frequently cause lower respiratory tract infections (LRTIs) in patients housed in intensive care units (ICUs). Relebactam, a novel diazabicyclooctane inhibitor of Ambler class A and C β-lactamases, in combination with imipenem-cilastatin, was approved by the United States Food and Drug Administration (FDA) in July 2019 for the treatment of adults with complicated intraabdominal and complicated urinary tract infections. A Phase III study of imipenem-relebactam for the treatment of patients with respiratory tract infections, including antimicrobial-resistant Gram-negative infections has also been completed. CLSI-defined broth microdilution methodology was used to determine MICs against non-Proteeae Enterobacteriaceae (NPE) and Pseudomonas aeruginosa collected from ICU patients with LRTIs at 26 United States hospitals in 2015-2017. Percent susceptibilities to imipenem-relebactam were 97.0, 66.4, and 98.1%, respectively, for all NPE (n=1298), imipenem-nonsusceptible NPE (n=113, of which 71% were Serratia marcescens), and MDR NPE (n=206), and 92.2, 77.2, and 79.6%, respectively, for all P. aeruginosa (n=638), imipenem-nonsusceptible P. aeruginosa (n=219), and MDR P. aeruginosa (n=225). Percent susceptibilities to imipenem-relebactam were 98.0-98.6% for cefepime-, ceftazidime-, and piperacillin-tazobactam-nonsusceptible NPE and 77.8-82.5% for cefepime-, ceftazidime-, and piperacillin-tazobactam-nonsusceptible P. aeruginosa. Generally, only slight variations in susceptibility were observed across United States census regions. Imipenem-relebactam may provide a valuable therapeutic option for the treatment of ICU patients with LRTI caused by Gram-negative bacilli resistant to commonly used β-lactams, as it demonstrated potent in vitro activity against the majority of tested β-lactam-nonsusceptible and MDR Gram-negative bacilli from ICU patients with LRTIs in United States hospitals.